MedTrace Logo

Safety of Etoricoxib (MK-0663) in Patients With Spondyloarthropathy (SpA)/Ankylosing Spondylitis (AS) in Sweden (EP07013.013.11.082)

NCT01327638 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 21108

Last updated 2024-05-10

No results posted yet for this study

Summary

The study is intended to provide additional post-marketing safety data regarding the use of etoricoxib for the indication of ankylosing spondylitis.

Conditions

  • Spondylarthropathies; Spondylitis, Ankylosing

Interventions

DRUG

etoricoxib

Patients with SpA/AS who took etoricoxib

DRUG

Other COX-2 inhibitor

Patients with SpA/AS who took other COX-2 inhibitors

DRUG

nsNSAIDs

Patients with SpA/AS who took nsNSAIDs

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-02-15
Primary Completion
2018-09-24
Completion
2018-12-06

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01327638 on ClinicalTrials.gov